Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to
the acquisition of DNA mutations and genomic instability in cancer. How genomic instability …

Homologous recombination–deficient (HRD) tumours, including those harbouring mutations
in the BRCA genes, are hypersensitive to treatment with inhibitors of poly (ADP-ribose) …

DNA double-strand breaks are the most critical DNA damage to cells, and their repair is
tightly regulated to maintain cellular integrity. Some cancers exhibit homologous …

Introduction: DNA double-strand breaks (DSBs) are toxic DNA lesions that can be repaired
by non-homologous end-joining (NHEJ) or homologous recombination (HR). Mutations in …

PARP inhibitors (PARPis) have remarkable antitumor activity in BRCA mutant ovarian
carcinoma. Emerging evidence has shown that responses to PARPis are not limited to …

Poly (ADP-ribose) polymerase 1 (PARP1) is an important component of the base excision
repair (BER) pathway as well as a regulator of homologous recombination (HR) and non …

Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA
repair pathway of clinical interest due to the sensitivity of homologous recombination …

Although DNA double-strand breaks (DSBs) are substrates for homologous recombination
(HR) repair, it is becoming apparent that DNA lesions produced at replication forks, for …

Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2
(BRCA2) deleterious variants were the first and, still today, the main biomarkers of poly …

PARP inhibitors have shown remarkable efficacy in the clinical management of several
BRCA-mutated tumors. This approach is based on the long-standing hypothesis that PARP …